Journal
GENOMICS
Volume 100, Issue 1, Pages 27-34Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygeno.2012.05.001
Keywords
PDMS microfluidic biochip; Kidney; Ifosfamide; Inflammation; Cancer; Transcriptomic; Drug target
Funding
- ANR [CP2D-Syxbioxprogram]
- foundation of the University of Technology in Compiegne La Fondation UTC pour l'innovation
Ask authors/readers for more resources
We investigated the behavior of renal cells cultivated in microfluidic biochips when exposed to 50 mu M of ifosfamide, an antineoplastic drug treatment. The microarray analysis revealed that ifosfamide had any effect in Petri conditions. The microfluidic biochips induced an early inflammatory response in the MDCK in the untreated cells. This was attributed to cells adapting to the dynamics and micro environment created by the biochips. This led to modulations in the mitochondria dysfunction pathway, the Nrf-2 and oxidative stress pathways and some related cancer genes. When exposed to 50 mu M of ifosfamide, we detected a modulation of the pathways related to the cancer and inflammation in the MDCK cultivated in the biochips via modulation of the ATM, p53, MAP Kinase, Nrf-2 and NFKB signaling. In addition, the genes identified and related proteins affected by the ifosfamide treatment in the biochips such as TXNRD1, HSP40 (DNAJB4 and DNAJB9), HSP70 (HSPA9), p21 (CDKN1A), TP53, IKBalpha (NFKBIA) are reported to be the molecular targets in cancer therapy. We also found that the integrin pathway was perturbed with the ifosfamide treatment Finally, the MYC protooncogene appeared to be a potential bridge between the integrin signaling and the anti-inflammatory response. (C) 2012 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available